The extended-MDR phenotype

Cytotechnology

Volumn 27, Issue 1-3, 1998, Pages 237-247

  Davey, Ross ^a   Davey, Mary ^b  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

Author keywords

Extended MDR; Glutathione; MRP; P glycoprotein

Indexed keywords

ALKYLATING AGENT; ANTIINFECTIVE AGENT; ANTIMETABOLITE; LIPOPHILIC COMPOUND; MULTIDRUG RESISTANCE; PHENOTYPE;

EID: 0032426965     PISSN: 09209069     EISSN: None     Source Type: Journal    
DOI: 10.1007/978-94-017-2374-9_15     Document Type: Article

References (38)

1. Barnouin K, Leier I, Jedlitschky G, Pourtier Manzanedo A, Konig J, Lehmann WD and Keppler D (1997) Multidrug resistance protein-mediated transport of chlorambucil and melphalan conjugated to glutathione. Brit J Cancer 77: 201-209.
2. Batist G, Torres-Garcia S, Demuys J, Greene D, Lehnert S, Rochon M and Panasci L (1989) Enhanced DNA cross-link removal: The apparent mechanism of resistance in a clinically relevant melphalan resistant human breast cancer cell line. Mol Pharmacol 36: 224-230.
3. Bielack SS, Kallenbach K, Looft G, Erttmann R and Winkler K (1995) Structurally modified anthracyclines retain activity in a cell line with simultaneous typical and atypical multidrug resistance. Anticancer Res 15: 1279-1284.
4. Boege F (1996) Analysis of eukaryotic DNA topoisomerases and topoisomerase-directed drug effects. Eur J Clin Chem Clin Biochem 34: 873-888.
5. Chao CC (1995) Lack of elevated drug efflux in adriamycinresistant immunoblastic B lymphoma cells with mdrl overexpression. FEES Lett 373: 285-290.
6. Chao CCK (1996) Cross-resistance to cis-diamminedichloroplatinum(ii) of a multidrug-resistant lymphoma cell line associated with decreased drug accumulation and enhanced DNA repair. Eur J Pharmacol 305: 213-222.
7. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM and Deeley RG (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650-1654.
8. Davey RA, Su GM, Hargrave RM, Harvie RM, Baguley BC and Davey MW (1997) The potential of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide to circumvent three multidrug-resistance phenotypes in vitro. Cancer Chemother Pharmacol 39: 424-430.
9. Davey R, Longhurst T, Davey M, Belov L, Harvie R, Hancox D and Wheeler H (1995) Drug resistance mechanisms and MRP expression in response to epirubicin treatment in a human leukaemia cell line. Leuk Res 19: 275-282.
10. Endicott JA and Ling V (1989) The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 58: 137-171.
11. Gazdar A, Carney D, Russell E, Sims H, Baylin S, Bunn Jr P, Guccion J and Minna J (1980) Establishment of continuous, clonable cultures of small-cell carcinoma of the lung which have amine precursor uptake and decarboxylation cell properties. Cancer Res 40:3502-3507.
12. Gottesman MM, Hrycyna CA, Schoenlein PV, Germann UA and Pastan I (1995) Genetic analysis of the multidrug transporter. Annu Rev Genet 29: 607-649.
13. Hamaguchi K, Godwin AK, Yakushiji M, O'Dwyer PJ, Ozols RF and Hamilton TC (1993) Cross-resistance to diverse drugs is as-sociated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res 53: 5225-5232.
14. Hannun YA (1997) Apoptosis and the dilemma of cancer chemotherapy. Blood 89: 1845-1853.
15. Ishikawa T, Bao JJ, Yamane Y, Akimaru K, Frindrich K, Wright CD and Kuo MT (1996) Coordinated induction of MRP/GS-X pump and gamma-glutamylcysteine synthetase by heavy metals in human leukemia cells. J Biol Chem 271: 14981-14988.
16. Kavallaris M (1997) The role of multidrug resistance-associated protein (MRP) expression in multidrug resistance. Anti-Cancer Drugs 8: 17-25.
17. Kellen JA (1994) Molecular interrelationships in multidrug resistance. Anticancer Res 14: 433-435.
18. Keppler D and Konig J (1997) Expression and localization of the conjugate export pump encoded by the MRP2 (cMRP/cMOAT) gene in liver. FASEB 11: 509-516.
19. Kool M, DeHaas M, Scheffer GL, Scheper RJ, Van Eijk MJT, Juijn JA, Baas F and Borst P (1997) Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 57: 3537-3543.
20. List AF, Spier CM, Cline A, Doll DC, Garewal H, Morgan R and Sandberg AA (1991) Expression of the multidrug resistance gene product (P-glycoprotein) in myelodysplasia is associated with a stem cell phenotype. Brit J Haematol 78: 28-34.
21. Little C, Nau M, Carney D, Gazdar A and Minna J (1983) Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature 306: 194-196.
22. Loe DW, Deeley RG and Cole SPC (1996) Biology of the multidrug resistance-associated protein, MRP. Eur J Cancer 32A: 945-957.
23. Marks DC, Belov L, Davey MW, Davey RA and Kidman AD (1992) The MTT cell viability assay for cytotoxicity testing in multidrug-resistant human leukemic cells. Leukemia Res 16: 1165-1173.
24. Marks DC, Davey MW, Davey RA, and Kidman AD (1993) Differentiation and multidrug resistance in response to drug treatment in the K562 human leukaemia cell line. Brit J Haematol 84: 83-89.
25. Marks DC, Su GMI, Davey RA and Davey MW (1996) Extended multidrug resistance in haemopoietic cells. Brit J Haematol 95: 587-595.
26. Masanek U, Stammler G and Volm M (1997) Messenger RNA expression of resistance proteins and related factors in human ovarian carcinoma cell lines resistant to doxorubicin, taxol and cisplatin. Anti-Cancer Drugs 8: 189-198.
27. Mattern J and Volm M (1995) Resistance mechanisms in human lung cancer. Invasion and Metastasis 15: 81-94.
28. Mellish KJ, Barnard CF, Kelland LR and Harrap KR (1994) Circumvention of acquired tetraplatin resistance in a human ovarian carcinoma cell line by a novel trans platinum complex, JM335 [trans ammine (cyclohexylamine) dichloro dihydroxo platinum (IV)]. Int J Cancer 59: 65-70.
29. O'Brien ML and Tew KD (1996) Glutathione and related enzymes in multidrug resistance. Eur J Cancer 32A: 967-978.
30. Roy SN and Horwitz SB (1985) A phosphoglycoprotein associated with taxol resistance in J774.2 cells. Cancer Res 45: 3856-3863.
31. Shen HX, Paul S, Breuninger LM, Ciaccio PJ, Laing MM, Helt M, Tew KD and Kruh GD (1996) Cellular and in vitro transport of glutathione conjugates by MRP. Biochemistry 35: 5719-5725.
32. Su GM, Davey MW, Davey RA and Kidman AD (1994) Development of extended multidrug resistance in HL60 promyelocytic leukaemia cells. Brit J Haematol 88: 566-574.
33. Su GM, Davey MW and Davey RA (1998) Induction of broad drug resistance in small cell lung cancer cells and its reversal by paclitaxel. Int J Cancer 76: 702-708.
34. Taniguchi K, Wada M, Kohno K, Nakamura T, Kawabe T, Kawakami M, Kagotani K, Okumura K, Akiyama S and Kuwano M (1996) A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res 56: 4124-4129.
35. Tew KD (1994) Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 54: 4313-4320.
36. Tjuljandin SA, Doig RG, Sobol MM, Watson DM, Sheridan WP, Morstyn G, Mihaly G and Green MD (1990) Pharmacokinetics and toxicity of two schedules of high dose epirubicin. Cancer Res 50: 5095-5101.
37. Yang LY, Trujillo JM, Siciliano MJ, Kido Y, Siddik ZH and Su YZ (1993) Distinct P-glycoprotein expression in two subclones simultaneously selected from a human colon carcinoma cell line by cis-diamminedichloroplatinum (II). Int J Cancer 53: 478-485.
38. Yang XW and Page M (1995) P-glycoprotein expression in ovarian cancer cell line following treatment with cisplatin. Oncol Res 7: 619-624.